|
Mar 21
|
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
|
|
Mar 18
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
|
|
Mar 12
|
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
|
|
Mar 11
|
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
|
|
Mar 4
|
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
|
|
Mar 2
|
Positive Signs As Multiple Insiders Buy NRx Pharmaceuticals Stock
|
|
Mar 1
|
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
|
|
Feb 27
|
/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./
|
|
Feb 26
|
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
|
|
Feb 26
|
NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
|
|
Feb 9
|
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
|
|
Feb 5
|
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon
|
|
Jan 2
|
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco
|
|
Jan 2
|
NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard
|
|
Dec 27
|
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
|
|
Nov 27
|
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
|
|
Aug 30
|
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
|
|
Aug 29
|
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
|
|
Apr 27
|
NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
|